

AWARD NUMBER: W81XWH-17-1-0152

TITLE: Identification of Novel Signaling Pathways in NF2

PRINCIPAL INVESTIGATOR: Robert Hennigan

CONTRACTING ORGANIZATION: Cincinnati Childrens Hospital
Medical Center
3333 Burnet Ave.
Cincinnati, OH 45229

REPORT DATE: July 2018

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE July 2018		2. REPORT TYPE Annual		3. DATES COVERED 1Jul2017 - 30Jun2018	
4. TITLE AND SUBTITLE Identification of Novel Signaling Pathways in NF2				5a. CONTRACT NUMBER W81XWH-17-1-0152	
				5b. GRANT NUMBER NF160078	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Robert Hennigan E-Mail: Robert.Hennigan@cchmc.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Cincinnati Childrens Hospital Medical Center 3333 Burnet Ave. Cincinnati, OH 45229				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Schwannomas are benign peripheral nerve tumors that are initiated by biallelic mutation of the <i>NF2</i> tumor suppressor gene, resulting in loss of function of the <i>NF2</i> gene product, merlin. Loss of merlin drives tumor formation but there is no consensus on the mechanism of merlin's tumor suppressor function. Merlin has no intrinsic catalytic activity, its function regulated by the proteins with which it interacts. We used proximity biotinylation and direct binding assays to perform a global proteomic analysis that identified 52 merlin-associated proteins. The majority of merlin proximal proteins are components of cell junctional signaling complexes including actin binding proteins and members of the Hippo pathway. This pattern of protein interactions suggests that merlin functions as part of a mechano-sensory signal transduction network. We hypothesize that the loss of merlin destabilizes or impairs assembly of these structures, causing abnormal, cancer causing signals. To test this hypothesis, we will again use proximity biotinylation to look for changes in key cell junction components in the presence or absence of merlin. We expect that the experiments described in this proposal will yield greater insight					
15. SUBJECT TERMS Neurofibromatosis Type 2, NF2, Merlin, Cell Junctions					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	10	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	Page
Introduction.....	4
Body.....	4-8
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusion.....	9
References.....	9-10
Appendices.....	N/A

Introduction

Neurofibromatosis Type 2 is an inherited disease characterized by bilateral schwannomas of the 8th cranial nerve and other tumors of the nervous system, including meningiomas and ependymomas. The tumor suppressor gene responsible for this disorder, NF2, encodes a 70 kDa member of the Ezrin-Radixin-Moesin (ERM) protein called merlin (1, 2). Merlin acts as a context dependent tumor suppressor that controls contact inhibition of growth (3, 4). Merlin has been implicated as a key regulator of multiple cellular functions including signal transduction, ubiquitination and intracellular trafficking (5-7). However, merlin does not possess catalytic activity and the precise mechanism by which merlin mediates these functions is unknown. We used a global proteomic strategy to take a comprehensive census of merlin associated proteins in Schwann cells. This interactome analysis identified merlin as a key component of cell-cell and cell-substrate junctions. We hypothesized that merlin is necessary for the assembly of cell junctions and their signaling complexes. Merlin loss would then result in the activation of oncogenic signal transduction cascades due to aberrant cell junction signaling. Our objective is to test this hypothesis by defining changes in cell junctional complexes and signaling molecules in the presence and absence of merlin.

Body

Specific Aims

Our objective is to test this hypothesis by defining changes in cell junctional complexes and signaling molecules in the presence and absence of merlin. We will carry out the following specific aims.

Aim 1 Test the hypothesis that merlin is necessary for the assembly of normal cell junction signaling complexes.

Rationale: If merlin is necessary for the assembly of cell junction signaling complexes then the composition of these complexes will change upon merlin loss. We will focus on two known cell junction signaling proteins, angiomin (Amot) and erbin (Erbbip2), that directly bind to merlin and were identified as merlin associated proteins in our proximity biotinylation screen (Fig. 1C) (8-10). Angiomin localizes to TJs and regulates the Hippo pathway (11, 12) while Erbin localizes to AJs and regulates the Ras-MAPK pathway (13, 14). Both are scaffold proteins that functionally interact with oncogenic signaling proteins (8, 15). We will define the interactome for both angiomin and erbin in both *Nf2* wild type and CRE infected *Nf2* null Schwann cells at high and low cell densities. Significant changes in the interactomes of these proteins, as defined by proximity biotinylation, will confirm the hypothesis that merlin is required for the assembly of angiomin and erbin cell junctional signaling complexes.

Aim 2 Test the hypothesis that merlin function is required for Schwann cell junction assembly.

Rationale: If merlin is necessary for the assembly of Schwann cell junctions then the composition of cell junction complexes will change upon merlin loss. To test this, we will generate a set of fusions between BirA^{R118G} and ZO-1 (Tjp1), α -actinin (Actn1) and vinculin (Vcn), proteins that were identified as in our preliminary experiments and are consensus components of TJs, AJs and FAs (Fig. 1C & Fig. 1D). We will use proximity biotinylation to define the composition of these junctional complexes in *Nf2* wild type and null Schwann cells at both high and low cell density. Significant changes will confirm that merlin is required for cell junction assembly.

Aim 3 Identify changes in merlin interactome in the confluent and subconfluent Schwann cells.

Rationale: Merlin is a mediator of contact inhibition of growth; therefore, merlin activity is induced at high cell density relative to low cell density. To identify merlin interactions that correlate with merlin's growth suppressive activity we will perform proximity biotinylation experiments using Merlin-BirA^{R118G} in sparse and dense Schwann cells. Identification of merlin interactions that are specific for high density, growth suppressive conditions will identify specific interacting proteins required for merlin mediated tumor suppression.


Aims 1 and 2
Crispr PITCH

We have made significant progress in constructing the plasmids required to insert BirA^{R118G} in frame C-terminal to the proteins described in the proposal, angiotensin, erbin, ZO1, α -actinin and vinculin. We have sequenced the first and last exons for these genes immortalized Nf2^{flox/flox} mouse cells. We have constructed and verified by sequencing the pCRIS-PITCH-BirAHygro C-terminal insertion plasmid and the pX330A-Empty-PITCH gene targeting plasmid. We have deferred construction of the pCRIS-PITCH-HygroBirA N-terminal insertion plasmid for reasons that will shortly become clear. We have also constructed and verified by sequencing the gene targeting and C-terminal insertion plasmids for angiotensin using three different gRNA target sites in the last exon are designed to fused BirA^{R118G} C-terminal to endogenous angiotensin. We then transfected immortalized Nf2^{flox/flox} mouse cells with the either the angiotensin directed plasmids or empty vector controls. The efficiency of gRNAs was evaluated in transient transfections in three ways.

- 1. PCR amplification of the last exon of the cells followed my T7 mismatch repair assay.
- 2. PCR amplification of the last exon of the angiotensin targeted and control cells followed by TIDE analysis to detect indels in the sequence trace (16).
- 3. Nested PCR amplifying the angiotensin last exon in then using primers specific for the BirA-N-terminus and the angiotensin C-terminus designed to detect the recombination product, followed by sequencing of any amplified band to confirm in-frame insertion

The results of these experiments were mixed. We were never able to observe evidence mismatches any of the gRNAs we designed by either T7 assay or TIDE analysis. Sequencing confirmed that recombination resulted in in-frame fusion (Figure 1c). We performed positive control experiments using the original PITCH reagents targeting the FBL gene transfected in human 293T cells. Previously, we had demonstrated that these reagents result in generation of the appropriate endogenous FBL-GFP fusion protein, validating the protocol and the efficiency of the gene specific gRNA. However, we were unable show that this proven gRNA worked in transient transfections, similar to our experience with angiotensin. Since these assays work well when used to evaluate gRNA efficacy in CRISPR mediated knockouts using lentivirus (described below), we therefore reasoned that the T7 mismatch and TIDE analysis were insufficiently sensitive to be used in transient transfection.

Despite our inability to confirm gRNA efficacy, we were able to PCR amplify the angiotensin-BirA recombination product (Figure 1B). Since we could detect the recombination product in a nested PCR assay (Fig 1c) we decided to place the Angiotensin-C-term transfected cells in selection with hygromycin. Within three weeks we selected 24 colonies of hygromycin resistant cells. However, we were unable to detect any colonies containing the angiotensin-BirA recombination product. We attempted this selection procedure for several other




angiomin directed gRNAs and also for the PITCH system targeting several other genes, including Nf2 itself. In each case, the appropriate recombination product can be detected by nested PCR, but stable recombinant clones were not found. These data indicate that recombination via CRISPR mediated MMEJ occurs, but that selection fails, suggesting a systemic problem with the PITCH system. The Crispr PITCH system requires antibiotic selection using either puromycin or hygromycin resistance genes expressed downstream of a T2A "self-cleaving" peptide sequence in the fusion protein (Figure 1). The experiments described in this proposal were designed to be performed in an immortalized mouse cell line that has a floxed Nf2 allele. We had known the concentration of puromycin and hygromycin required for selection in these cells was quite high relative to other cell lines in the lab (5 $\mu\text{g}/\text{ml}$ vs 0.5 $\mu\text{g}/\text{ml}$ puro and 500 $\mu\text{g}/\text{ml}$ hygro vs 50 $\mu\text{g}/\text{ml}$). We suspect that a high concentration of antibiotics requires high levels of the relevant resistance genes for successful selection. Since this system expresses the resistance marker under control of the promoter for the knock in gene, the levels of this protein may be too low to select for the desired recombination event, contributing to our inability to select for knock out clones. The hygromycin resistant colonies we identified were the result of random integration resulting in high enough hygro resistance gene expression for colony formation. To address this problem, we are investigating several possible solutions.

1. We will change cell system to cells that are more sensitive to puromycin and hygromycin in the hope that lower levels of the hygro and puro resistance genes will enable practical selection.
2. We will use a lentiviral gRNA-Cas9 system (pLentiCRISPRv2puro and pLentiCRISPRv2hygro) to separately evaluate the efficacy of gRNAs in populations where 100% of the cells are expressing the gRNA of interest and the BirA Hygromycin replacement vector.
3. Construct the described BirA fusion proteins in established Dox inducible system (17) as described in the pitfalls section of the proposal.

NF2 Null Human Schwann Cell Line

We decided to switch to a different cell system consisting of a human Schwann cell line immortalized with telomerase and CDK4 (18) called iHSC-1 λ . These cells are that is sensitive to puro at 0.5 $\mu\text{g}/\text{ml}$ and hygro at 50 $\mu\text{g}/\text{ml}$. We generated merlin null cell lines via

Figure 2 Merlin Null Immortalized Human Schwann Cells (iHSC)



A. A map of the first exon of human NF2 showing the sites of two (of three) gRNA sites, designated T5 and T9, designed to introduce indels to disrupt merlin expression in iHSC-1 λ cells.

B. T7 mismatch assay of PCR amplified NF2 exon sequences from parental iHSC-1 λ cells (1L), puromycin resistant cells infected with lentivirus expressing a Cas9 and a scrambled gRNA sequence (SCR) or lentivirus expressing a Cas9 and a the T5 or T9 NF2 exon directed gRNA sequences (T5, T9). PCR products were denatured, reannealed then either untreated (-) or treated with T7 endonuclease (+). Mismatched are identified by the presence of cleavage products.

C. TIDE analysis showing the presence of Indels in PCR amplified NF2 exon 1 derived from either T5 or T9 (top) but not from scrambled control (SCR).

D. Western blots of cell lysates derived from parental iHSC-1 λ cells (1L), scrambled control (SCR), Exon 1-T5 (T5), Exon 1-T9 (T9), or Exon 2-T2 (T2) probed with antibodies to merlin of actin.

E. Five-day growth curves for all cell lines described above.


Crispr using lentivirus expressing Cas9 and gRNAs targeted to sites in the first or second exon of the human NF2 gene. Three gRNA sites were designed using CCTop software and the efficiency of each gRNA was evaluated using T7 endonuclease mismatch repair assays and TIDE sequencing analysis exactly as described in our proposal (Figure 2 a-c). After selection with puromycin (at 0.5 μ g/ml) pools of clones (iHSC-1 λ -T2, T5 and T9) were lysed and probed for merlin expression. Merlin proteins expression was lost in all three tested gRNAs (Figure 2d). Growth curves demonstrated that the merlin null cell lines had faster growth rates and reached higher densities than the parental iHSC-1 λ or control lenti infected cells expressing a scrambled gRNA (iHSC-1 λ -SCN), showing that they expressed the merlin null phenotype.

This experiment generated another immortalized merlin deficient Schwann cell in which perform the PITCh assay described in our proposal that is much less resistant to hygromycin. Furthermore, these experiments demonstrate that lentiviral infection is a more efficient way to deliver PITCh reagent of Schwann cells than transient transfection. We are investigating the possibility of adapting the BirA-T2A-Hygro replacement cassette for lentiviral delivery, possibly using integration deficient lentivirus, to increase the probability of selecting for rare recombination events.

Direct vs Indirect Merlin Binding

The overall objective of this proposal essentially leverages our experience with BirA^{R118G} based proximity biotinylation combined with Crispr mediated knock in experiments to produce a comprehensive interactome of the cell junctional structures that merlin interacts with. However, proximity biotinylation does not distinguish between proteins that directly bind to merlin, those that associate with merlin via another molecule or those that are simply in close proximity. We therefore designed a rapid, sensitive secondary screen that utilizes nanobody-based pulldown assay and a merlin -luciferase probes and distinguish amongst these possibilities (Fig. 3a). We selected a representative set of 10 merlin proximal proteins, including two known merlin binding proteins, angiomin and Lats1, to further evaluate. The other proteins are α -actinin, afadin, angiomin, ASPP2, Band 4.1B, Lats1, Myosin IIB, Scribble, Vinculin and ZO-1. The positive control angiomin had the highest merlin-NanoLuc associated activity. ASPP2 and Lats1 had moderate levels, 30 and 18-fold over control, respectively (Figure 3b). The remaining proteins, afadin, Band 4.1B, Myosin IIB, Scribble, and ZO-1 all had, exceeding the threshold of two-fold over the RFP negative control. In direct interaction assays merlin directly binds to 3 of the proteins we tested, angiomin, Lats-1 and ASPP2. Angiomin bound most effectively, 25-fold greater than the negative control, interacts with merlin with a high apparent affinity, consistent with the 1 μ M Kd described in the literature (19). ASPP2 and Lats-1 bind 2.5 and 4.3-fold above control, respectively (Figure 3c). Of interest in this proposal is the finding that with the exception of angiomin the merlin associated proteins target3d in aim 1 (erbin) and aim 2 ZO-1 (Tjp1), α -actinin (Actn1) and vinculin (Vcn), do not bind directly but instead interact indirectly as components of a merlin containing complex. This result does not affect how we carry out the experiments described in aims 1 and 2 it merely clarifies the context within which merlin functions within these structures, arguing against the idea that merlin is a critical structural component and supporting the idea that merlin interaction may be a transitory consequence of signaling. The experiments described in this proposal will still shed light on merlin function in this context.

Figure 3 Merlin Binding Screen



Key Research Accomplishments.

- Construction of PITCh reagents for angiotensin, NF2
- Initial evaluation of PITCh procedure.
- Generation of alternative cell line to solve the selection problems encountered in our initial PITCh experiments.
- Generation of conventional Dox-inducible BirA fusion constructs as a back-up strategy.
- Development of a secondary screen that unambiguously distinguishes between direct merlin binding proteins. This system revealed that merlin binds to cell junctional proteins indirectly via an unknown intermediate. Execution of the experiments described in the proposal will be greatly facilitated by adapting this protocol as a way of fully delineating merlin's relationship to these structures.

Reportable Outcomes

None

Conclusion

We have made significant progress in testing the practicality of the PITCh protocol, a method that remains critical for the efficient generation of multiplex proximity biotinylation experiments that is necessary for a full understanding of the role that merlin plays in cell junctional signaling. We have identified a significant roadblock to achieving this goal in our inability to identify stable recombinant clones containing in frame gene of interest-BirA fusions, despite evidence that the recombination event occurs as predicted. We have outlined several steps we hope to ameliorate this problem, including adopting a more antibiotic sensitive cell background and changing to a more efficient lentiviral delivery system. We are currently in the process of evaluating these steps. We also developed a simple, powerful secondary screen that successfully addresses a significant weakness of the BirA proximity biotinylation strategy, distinguishing between direct and indirect interactions. We are confident that we will quickly determine if the PITCh system is viable or aggressively move to the backup strategy involving the generation of Dox-inducible cell lines as described in the original proposal.

References

1. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. *Nature*. 1993;363(6429):515-21. Epub 1993/06/10. PubMed PMID: 8379998.
2. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. *Cell*. 1993;75(4):826. Epub 1993/11/19. PubMed PMID: 8242753.
3. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipiek CA, Gutmann DH, Ponta H, Herrlich P. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. *Genes & development*. 2001;15(8):968-80. PubMed PMID: 11316791; PMCID: 312675.
4. Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. *The Journal of cell biology*. 2005;171(2):361-71. PubMed PMID: 16247032; PMCID: 2171182.
5. McClatchey AI. Merlin and ERM proteins: unappreciated roles in cancer development? *Nature reviews Cancer*. 2003;3(11):877-83. PubMed PMID: 14668818.
6. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. *Cell*. 2010;140(4):477-90. PubMed PMID: 20178741; PMCID: 2828953.
7. Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, Lampin A, Niwa-Kawakita M, Kalamarides M, Giovannini M. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. *Oncogene*. 2009;28(6):854-65. PubMed PMID: 19029950.
8. Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N, Persson NL, Shimono A, Speicher DW, Marmorstein R, Holmgren L, Kissil JL. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. *Cancer cell*. 2011;19(4):527-40. PubMed PMID: 21481793; PMCID: 3075552.
9. Rangwala R, Banine F, Borg JP, Sherman LS. Erbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between Merlin and adherens junction protein complexes in Schwann cells. *The Journal of biological chemistry*. 2005;280(12):11790-7. PubMed PMID: 15659388.
10. Wilkes MC, Repellin CE, Hong M, Bracamonte M, Penheiter SG, Borg JP, Leof EB. Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-beta. *Developmental cell*. 2009;16(3):433-44. PubMed PMID: 19289088; PMCID: 2792748.
11. Bratt A, Birot O, Sinha I, Veitonmaki N, Aase K, Ernkqvist M, Holmgren L. Angiomotin regulates endothelial cell-cell junctions and cell motility. *The Journal of biological chemistry*. 2005;280(41):34859-69. PubMed PMID: 16043488.
12. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. *The Journal of biological chemistry*. 2011;286(9):7018-26. PubMed PMID: 21224387; PMCID: 3044958.
13. Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H, Fournier E, Adelaide J, Margolis B, Birnbaum D. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. *Nature cell biology*. 2000;2(7):407-14. PubMed PMID: 10878805.
14. Huang YZ, Zang M, Xiong WC, Luo Z, Mei L. Erbin suppresses the MAP kinase pathway. *The Journal of biological chemistry*. 2003;278(2):1108-14. PubMed PMID: 12379659.
15. Kolch W. Erbin: sorting out ErbB2 receptors or giving Ras a break? *Sci STKE*. 2003;2003(199):pe37. PubMed PMID: 12966186.
16. Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res*. 2014;42(22):e168. Epub 2014/10/11. PubMed PMID: 25300484; PMCID: PMC4267669.
17. Hennigan RF, Fletcher J, Bogard M, Olsen N, Guard S, Ratner N. The Interactome for the NF2 Tumor Suppressor Merlin. 2018.

18. Li H, Chang LJ, Neubauer DR, Muir DF, Wallace MR. Immortalization of human normal and NF1 neurofibroma Schwann cells. *Lab Invest.* 2016;96(10):1105-15. Epub 2016/09/13. PubMed PMID: 27617404.
19. Li Y, Zhou H, Li F, Chan SW, Lin Z, Wei Z, Yang Z, Guo F, Lim CJ, Xing W, Shen Y, Hong W, Long J, Zhang M. Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway. *Cell research.* 2015;25(7):801-17. PubMed PMID: 26045165; PMCID: PMC4493278.